Home › Companies › REGENERON PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and REGENERON PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore REGENERON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are REGENERON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: N. Anthony Coles, M.D. | 110,481,731 | 1,873,397 | 99,413 | -- | 4,213,730 | Majority: yes |
| Elect Director: Kathryn Guarini, Ph.D. | 111,988,738 | 359,659 | 106,144 | -- | 4,213,730 | Majority: yes |
| Elect Director: Arthur F. Ryan | 81,009,658 | 31,288,101 | 156,782 | -- | 4,213,730 | Majority: yes |
| Elect Director: George L. Sing | 102,751,205 | 9,574,839 | 128,497 | -- | 4,213,730 | Majority: yes |
| Elect Director: David P. Schenkein, M.D. | 106,839,998 | 5,501,139 | 113,404 | -- | 4,213,730 | Majority: yes |
| Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, | 111,350,016 | 5,257,636 | 60,619 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 25, 2024 was ap | 106,667,264 | 5,579,814 | 207,463 | -- | 4,213,730 | Majority: yes |
| Proposal 4: Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements was approved based upon the following votes: | 85,900,254 | 26,365,621 | 188,666 | -- | 4,213,730 | Majority: yes |
Source: REGENERON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-20 — read the filing on EDGAR.
Each item below shows how the 1,000 asset managers that disclosed a REGENERON PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of REGENERON PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2024-06-14.
Combines 26 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on ”): 106,667,264 for, 5,579,814 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 987 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 21,222,962 | 0 | 0 | 0 | For |
| Capital Group | 15,179,348 | 0 | 0 | 0 | For |
| JPMorgan | 11,811,146 | 1,504 | 0 | 0 | For |
| Vanguard | 9,634,402 | 0 | 0 | 0 | For |
| BlackRock | 6,890,612 | 0 | 0 | 0 | For |
| New York Life | 6,023,224 | 0 | 0 | 0 | For |
| State Street | 4,046,145 | 36,625 | 0 | 0 | For |
| Dodge & Cox | 4,062,830 | 0 | 0 | 0 | For |
| Putnam | 2,597,151 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,374,773 | 0 | 0 | 0 | For |
| Invesco | 1,829,508 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,594,984 | 0 | 0 | 0 | For |
| American Century | 1,408,963 | 0 | 0 | 0 | For |
| MCDONALD CAPITAL INVESTORS INC/CA | 1,363,499 | 0 | 0 | 0 | For |
| Charles Schwab | 1,333,527 | 0 | 0 | 0 | For |
| Wellington | 1,047,505 | 0 | 0 | 0 | For |
| Northern Trust | 974,140 | 6,952 | 0 | 0 | For |
| AllianceBernstein | 752,307 | 0 | 0 | 0 | For |
| Amundi | 0 | 744,567 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 631,507 | 0 | 0 | 0 | For |
| Man Group plc | 625,250 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 580,688 | 0 | 0 | Against |
| Nuveen | 576,045 | 0 | 0 | 0 | For |
| Dimensional | 557,248 | 0 | 0 | 0 | For |
| Neuberger Berman | 554,297 | 0 | 0 | 0 | For |
Showing the 25 largest of 987 asset managers. See all 987 in the interactive database.
Meeting held 2024-06-14.
Combines 9 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm”): 111,350,016 for, 5,257,636 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 193 asset managers below cast 99.7% of the shares they voted on this item FOR (48,645,248 for, 116,596 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,231,279 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,781 | 39 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,574 | 0 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 193 asset managers. See all 193 in the interactive database.
Meeting held 2024-06-14.
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: N. Anthony Coles, M.D.”): 110,481,731 for, 1,873,397 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 192 asset managers below cast 99% of the shares they voted on this item FOR (48,111,232 for, 642,137 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,654,600 | 38,756 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,230,718 | 561 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,775 | 45 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,330 | 186 | 0 | 0 | For |
| Equitable | 202,181 | 5,393 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.
Meeting held 2024-06-14.
Combines 7 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kathryn Guarini, Ph.D.”): 111,988,738 for, 359,659 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 192 asset managers below cast 99.9% of the shares they voted on this item FOR (48,753,352 for, 15 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,231,279 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,820 | 0 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,574 | 0 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.
Meeting held 2024-06-14.
Combines 5 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Arthur F. Ryan”): 81,009,658 for, 31,288,101 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 192 asset managers below cast 80% of the shares they voted on this item FOR (39,077,581 for, 9,675,784 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,495,109 | 2,198,247 | 0 | 0 | For |
| Vanguard | 9,170,005 | 6,700 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,227,666 | 3,613 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 224 | 1,115,596 | 0 | 0 | Against |
| Invesco | 0 | 782,194 | 0 | 0 | Against |
| American Century | 0 | 653,923 | 0 | 0 | Against |
| Charles Schwab | 0 | 633,970 | 0 | 0 | Against |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 0 | 492,148 | 0 | 0 | Against |
| MFS | 0 | 352,388 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 0 | 321,265 | 0 | 0 | Against |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 37,686 | 184,830 | 0 | 0 | Against |
| Equitable | 145,249 | 62,325 | 0 | 0 | For |
| PIONEER FUND /MA/ | 0 | 199,473 | 0 | 0 | Against |
| Aberdeen | 0 | 167,165 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.
Meeting held 2024-06-14.
Combines 7 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 106,839,998 for, 5,501,139 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 192 asset managers below cast 98% of the shares they voted on this item FOR (47,921,465 for, 831,903 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,229,443 | 1,836 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,781 | 39 | 0 | 0 | For |
| Invesco | 0 | 782,194 | 0 | 0 | Against |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,157 | 417 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.
Meeting held 2024-06-14.
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: George L. Sing”): 102,751,205 for, 9,574,839 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 192 asset managers below cast 96% of the shares they voted on this item FOR (46,955,329 for, 1,798,041 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,654,600 | 38,756 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,230,718 | 561 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 553 | 1,115,267 | 0 | 0 | Against |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,330 | 186 | 0 | 0 | For |
| Equitable | 202,181 | 5,393 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.
Meeting held 2024-06-14.
Combines 4 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements was approved based upon the following votes:”): 85,900,254 for, 26,365,621 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 188 asset managers below cast 98% of the shares they voted on this item FOR (44,615,434 for, 723,206 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,654,600 | 38,756 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,596 | 224 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,330 | 186 | 0 | 0 | For |
| Equitable | 202,181 | 5,393 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
| ProShares | 137,257 | 0 | 0 | 0 | For |
| Hartford | 134,871 | 0 | 0 | 0 | For |
Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.
Meeting held 2024-06-14.
77% Majority: yes · of votes cast
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements was approved based upon the following votes:”): 85,900,254 for, 26,365,621 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 8 asset managers below cast 100% of the shares they voted on this item FOR (3,414,727 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,231,279 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Empower | 12,699 | 0 | 0 | 0 | For |
| Managed Account Series | 2,661 | 0 | 0 | 0 | For |
| Brighthouse | 1,646 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 897 | 0 | 0 | 0 | For |
| Symmetry Panoramic Trust | 149 | 0 | 280 | 0 | Abstain |
| Warren Street Wealth Advisors, LLC | 122 | 0 | 0 | 0 | For |
Reported under meeting date 2023-06-09; no official results on file for that date (outside the 2023-2024 season's 1 July to 30 June window; reported in this season's filings).
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (2,185,600 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Baron Financial Group, LLC | 2,000,000 | 0 | 0 | 0 | For |
| BANCO BILBAO VIZCAYA ARGENTARIA, S.A. | 185,600 | 0 | 0 | 0 | For |
Meeting held 2025-06-13 (outside the 2023-2024 season's 1 July to 30 June window; reported in this season's filings).
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (385 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Meixler Investment Management, Ltd. | 368 | 0 | 0 | 0 | For |
| Foster Victor Wealth Advisors, LLC | 17 | 0 | 0 | 0 | For |
Ranked by the number of REGENERON PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 107,800,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 19.69% |
| 2 | Capital Group | 14.08% |
| 3 | JPMorgan | 10.96% |
| 4 | Vanguard | 8.94% |
| 5 | BlackRock | 6.39% |
| 6 | New York Life | 5.59% |
| 7 | State Street | 3.79% |
| 8 | Dodge & Cox | 3.77% |
| 9 | Putnam | 2.41% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.20% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR LLC | 9.57% | DEF14A |
| The Vanguard Group, Inc. | 8.20% | DEF14A |
| BlackRock, Inc. | 8.01% | DEF14A |
| JPMorgan Chase & Co. | 6.70% | DEF14A |
| State Street | 4.49% | 13F |
| Capital International | 2.90% | 13F |
| Geode Capital | 2.20% | 13F |
| Leonard S. Schleifer, M.D., Ph.D. | 1.60% | DEF14A |
| Franklin Templeton | 1.57% | 13F |
| Morgan Stanley | 1.35% | 13F |
Percentages above are of 107,800,000 shares outstanding, as reported by REGENERON PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REGENERON PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At REGENERON PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-14, in the 2023-2024 proxy season, 1,000 asset managers reported how they voted in their SEC Form N-PX filings, covering 9,942 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Proposal to approve, on an advisory basis, executive compensation. — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: REGENERON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-20.
REGENERON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.